RadNet, Inc. (NASDAQ:RDNT) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

On March 2, 2026, RadNet, Inc. (NASDAQ:RDNT) announced the acquisition of Paris-based Gleamer SAS for up to €230 million. The acquisition positions the company’s subsidiary, DeepHealth, as the world’s largest radiology AI provider. Gleamer services 700 global contracts. It reported a 90% ARR growth rate between 2022 and 2025 and is expected to reach $30 million in ARR by 2026. Structured as an all-cash transaction, Gleamer’s takeover integrates FDA-cleared X-ray and musculoskeletal AI into DeepHealth’s portfolio, covering all major imaging modalities. RadNet, Inc. (NASDAQ:RDNT) anticipates significant cost effectiveness and diagnostic automation capabilities from the integration in the third quarter of 2026.

Following the acquisition, RadNet, Inc. (NASDAQ:RDNT)’s DeepHealth unveiled the industry’s most comprehensive native clinical AI portfolio at ECR 2026 on March 4, 2026. The platform integrates Gleamer’s AI solutions for MR, CT, X-ray, Ultrasound, and Mammography to establish clinical AI suites covering breast, chest, neuro, and prostate care. With these modular suites, DeepHealth aims to stage-shift disease through earlier detection and automated reporting.

Founded in 1981, RadNet, Inc. (NASDAQ:RDNT) is the largest U.S. operator of outpatient diagnostic imaging centers. Its headquarters is in California.

While we acknowledge the potential of RDNT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey on Google News.